We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
cbdMD Inc | AMEX:YCBD | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.013 | 1.51% | 0.875 | 0.909 | 0.87 | 0.87 | 16,394 | 14:49:27 |
cbdMD, Inc.
|
(Exact name of registrant as specified in its charter)
|
North Carolina
|
47-3414576
|
(State or other jurisdiction of incorporation or
organization)
|
(I.R.S. Employer Identification Number)
|
|
|
8845 Red Oak Boulevard, Charlotte, NC
|
28217
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
|
|
Emerging growth company
|
☒
|
Title
of securities to be registered
|
Amount
to be
registered
(1)
|
Proposed
maximum offering price per share (2)
|
Proposed
maximum aggregate offering price
|
Amount
of
registration
fee
|
|
|
|
|
|
Common stock, par
value $0.001 per share
|
5,000,000
|
$3.93
|
$19,650,000
|
$2,143.82
|
(1)
|
Pursuant
to Rule 416(c) under the Securities Act of 1933, as amended, this
registration statement also covers an indeterminate number of
additional shares of common stock that may be offered or issued in
the event of a stock dividend, reverse stock split, split-up,
recapitalization, forfeiture of stock under those plans, or other
similar event.
|
|
|
(2)
|
Estimated
solely for the purpose of calculating the registration fee in
accordance with Rules 457(c) and (h) of the Securities Act of 1933,
as amended. The price per share and aggregate offering price are
calculated on the basis of the average of the high and low sale
prices of our common stock on the NYSE American on March 30, 2021,
in accordance with Rule 457(c) under the Securities Act of 1933, as
amended.
|
•
|
our Annual Report on Form 10-K for the fiscal year ended September
30, 2020 as filed with the SEC on December 22, 2020;
|
•
|
our
Quarterly Report on Form 10-Q for the period ended December 31,
2020 as filed with the SEC on February 9, 2021;
|
•
|
our
Current Reports on Form 8-K as filed with the SEC on January 14,
2021, January 15, 2021, February 16, 2021, March 4, 2021, March 11,
2021, March 15, 2021 and March 16, 2021;
|
•
|
our definitive proxy statement on Schedule 14A as filed with the
SEC on January 25, 2021; and
|
•
|
the description of our common stock contained in our Registration
Statement on Form 8-A as filed with the SEC on November 15, 2017
and any further amendment or report filed hereafter for the purpose
of updating such description.
|
|
cbdMD, Inc.
|
||
|
|
|
|
|
By:
|
/s/
T. Ronan Kennedy
|
|
|
|
T. Ronan Kennedy,
|
|
|
|
Chief Financial Officer and Chief Operating Officer
|
|
Name
|
|
Positions
|
|
Date
|
|
|
|
|
|
/s/ Martin A. Sumichrast
Martin
A. Sumichrast
|
|
Chairman of the Board of Directors, co-Chief Executive Officer
(co-principal executive officer)
|
|
April
1, 2021
|
|
|
|
|
|
/s/ Raymond S. Coffman
Raymond
S. Coffman
|
|
co-Chief Executive Officer (co-principal executive officer) and
Director
|
|
April
1, 2021
|
|
|
|
|
|
/s/ T. Ronan Kennedy
T.
Ronan Kennedy
|
|
Chief Financial Officer (principal financial and accounting
officer)
|
|
April
1, 2021
|
|
|
|
|
|
/s/ Bakari Sellers
Bakari
Sellers
|
|
Director
|
|
April
1, 2021
|
|
|
|
|
|
/s/ Peter J. Ghiloni
Peter
J. Ghiloni
|
|
Director
|
|
April
1, 2021
|
|
|
|
|
|
/s/ Scott G. Stephen
Scott
G. Stephen
|
|
Director
|
|
April
1, 2021
|
|
|
|
|
|
/s/ William F. Raines, III
William
F. Raines, III
|
|
Director
|
|
April
1, 2021
|
|
|
|
|
|
/s/ Sim Farar
Sim
Farar
|
|
Director
|
|
April
1, 2021
|
|
|
|
|
Incorporated by Reference
|
|
Filed or
Furnished
|
||||
No.
|
|
Exhibit Description
|
|
Form
|
|
Date Filed
|
|
Number
|
|
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
2021
Equity Compensation Plan
|
|
8-K
|
|
1/14/21
|
|
10.1
|
|
|
|
|
Opinion
of Pearlman Law Group LLP
|
|
|
|
|
|
|
|
Filed
|
|
|
Opinion
of the Gavigan Law, PLLC
|
|
|
|
|
|
|
|
Filed
|
|
|
Consent
of Cherry Bekaert LLP
|
|
|
|
|
|
|
|
Filed
|
|
|
Consent
of Pearlman Law Group LLP (included in Exhibit 5.1)
|
|
|
|
|
|
|
|
Filed
|
|
|
Consent
of the Gavigan Law, PLLC (included in Exhibit 5.2)
|
|
|
|
|
|
|
|
Filed
|
1 Year cbdMD Chart |
1 Month cbdMD Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions